IL1B and Huntington disease: Although we did see a partial (40%) inhibition of TcdB‐mediated IL‐1β response in monocytes from FMF patients, with a large inter‐patient variability, this inhibition was consistent and almost total (86%) in HD monocytes, thus confirming that toxin‐mediated Pyrin inflammasome activation is less sensitive to colchicine inhibition in FMF patients than in HD monocytes (Fig 3B and Appendix Fig S5).